Table 5 Indirect comparison (MTC analysis) of IVT-AFL 2q8 versus IVR 0.5 mg PRN for 12-month safety outcomes

All AEs

5 studies (n = 1739)*

RR = 0.79 [0.55–1.10]

RR = 0.88 [0.64–1.15]

OR = 0.61 [0.29–1.26]

OR = 0.58 [0.18–1.82]

All serious AEs

5 studies (n = 1739)*

RR = 0.76 [0.47–1.26]

RR = 0.82 [0.47–1.42]

OR = 0.71 [0.39–1.32]

OR = 0.74 [0.31–1.72]

All serious ocular AEs

5 studies (n = 1739)*

RR = 0.28 [0.06–1.24]

RR = 0.30 [0.05–2.49]

OR = 0.27 [0.05–1.25]

OR = 0.28 [0.05–2.58]

All serious non-ocular AEs

4 studies (n = 1343)**

RR = 0.60 [0.32–1.14]

RR = 0.67 [0.29–1.66]

OR = 0.53 [0.24–1.17]

OR = 0.53 [0.12–2.11]

All ocular AEs

4 studies (n = 1343)**

RR = 0.75 [0.54–1.05]

RR = 0.85 [0.58–1.25]

OR = 0.60 [0.32–1.09]

OR = 0.58 [0.16–1.87]

All non-ocular AEs

3 studies (n = 1215)***

RR = 1.09 [0.87–1.40]

RR = 1.03 [0.80–1.56]

OR = 1.27 [0.65–2.42]

OR = 1.22 [0.23–6.18]

Eye pain

4 studies (n = 1343)**

RR = 0.98 [0.38–2.70]

RR = 0.96 [0.23–3.91]

OR = 0.97 [0.34–2.94]

OR = 0.95 [0.17–4.75]

Cataract

3 studies (n = 1215)***

RR = 3.93 [0.77–32.74]

RR = 3.83 [0.52–43.72]

OR = 4.09 [0.76–34.86]

OR = 4.16 [0.49–50.98]

Hypertension

4 studies (n = 1343)**

RR = 0.95 [0.44–2.07]

RR = 0.95 [0.37–2.55]

OR = 0.95 [0.40–2.22]

OR = 0.94 [0.28–3.14]

All causes of mortality

3 studies (n = 1215)***

RR = 2.90 [0.20–50.4]

RR = 2.76 [0.13–79.02]

OR = 3.06 [0.18–60.01]

OR = 2.83 [0.11–85.27]